4D Molecular Therapeutics Inc (FDMT) Stock Analysis

4D Molecular Therapeutics Inc (FDMT) is a publicly traded company in the HEALTHCARE sector. It trades at $9.27, carries a market capitalization of $518.06M. This page summarizes the public market data, fundamentals, and frequently asked questions for FDMT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

4D Molecular Therapeutics Inc currently has a Neutral sentiment score of 0.03.

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Emeryville, California, dedicated to pioneering advanced therapeutics using its proprietary adeno-associated virus (AAV) vector platform. The company is at the forefront of addressing critical unmet medical needs in ophthalmology, neurology, and rare diseases, with a strong focus on transforming patient outcomes through innovative gene therapies. With a well-developed pipeline and strategic collaboration...

GNG Research Analysis

GNG Research scores 4D Molecular Therapeutics Inc (FDMT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FDMT.

Frequently Asked Questions

Does FDMT pay dividends?

4D Molecular Therapeutics Inc (FDMT) does not currently pay a regular dividend.

What is FDMT's market cap?

4D Molecular Therapeutics Inc (FDMT) has a market capitalization of $518.06M with a current stock price of $9.27.